IGMPI Approvals & Accreditation : Approved by Quality Council of India (QCI) & Accredited Vocational Institution of Ministry of HRD, Government of India, Approved Training Institute of Food Safety and Standards Authority of India (FSSAI), Recognized by Department of Industrial Policy & Promotion, Ministry of Commerce & Industry, Government of India, An ISO 9001:2015 Certified Organisation registered under The Societies Registration Act,1860 Government of India Empanelled under Ministry of Horticulture and Food Processing, Government of Uttar Pradesh, Affiliated with Life Sciences and Food Industry Sector Skills Council (SSC)
Trusted by organizations & training participants in over 30 countries. Training | Certification | Education | Research

  • Positive results reported from Udenafil Phase III FUEL Trial by Mezzion Pharma to treat adolescents with SVHD who have undergone Fontan procedure
  • Novartis Phase III PARAGON-HR study failure of sacubitril/valsartan versus active comparator valsartan in HFpEF patients
  • Experimental novel rheumatoid arthritis drug successful in final Phase of Clinical Trials
  • Pain reduction in brain due to antidepressant SNRI medications
  • New clinical trial regulations appreciated by experts
  • Experimental novel rheumatoid arthritis drug successful in final Phase of Clinical Trials
  • Early gastric cancer diagnosis using AI
  • Alzheimer’s prevention clinical trials ended by Novartis, Amgen and Banner
  • Study published about Scion’s TNM™ device
  • Safety demonstration of sustained Niagen Supplementation and optimal dosing levels by Nicotinamide Riboside study
  • Triplet therapy of Pierre Fabre plays significant part in BRAF V600E-mutant metastatic colorectal Cancer
  • Multicenter, single arm, phase-2 study for combination of Obinutuzumab and Lenalidomide for relapsed or refractory follicular B-cell Lymphoma (GALEN)
  • Boston Biomedical announced discontinuation of Phase3 CanStemIIIP study of Napabucasin for treatment of metastatic Pancreatic Cancer due to futility
  • Genentech’s Phase III trial successful for comparable efficacy between Xofluza and Tamiflu
  • Sponsors urged by European regulators to publish Clinical trial results
  • Positive Results demonstrating Improvement in Disability and Quality of Life through Fremanezumab Phase IIIb FOCUS study
  • Phase 3 Revatio (Sildenafil Citrate) trial results announced by Pfizer
  • Frozen embryo transfers fail to deliver any improvement during IVF process
  • E8(R1) Draft Guideline: ICH
  • New Guidance on Off-Label drug benefits in trials: Health Canada
  • Pomegranate's Anti-aging compound wins during human clinical trials
  • BioCell Technology Announced BioCell Collagen®
  • Novartis Cosentyx® showed efficacy in psoriatic arthritis manifestations
  • TrialAssure launches clinical trial summaries portal
  • BCM-95 Curcugreen:Osteoarthritis treatment
  • US FDA draft guideline on clinical trial diversity augmentation
  • Roche, AbbVie become successful in Venclyxto Phase III results
  • Positive results announced by RemeGen Ltd. for RC48 clinical trial in HER2-Positive Metastatic or Unresectable urothelial cancer
  • Phase II Clinical Trial will be initiated by Vanessa Research to treat rare pediatric disease
  • First line Cholangiocarcinoma therapy announced by Incyte
  • Significant improvements observed for new inhaled treatment by Novartis during phase II data
  • First phase clinical trials cleared for novel Alzheimer’s drug
  • Collaboration between US-China: Acceleration in Clinical Trials
  • Novel Designs for Clinical Trials
  • Combination therapy for aggressive brain tumor patients
  • Continuous Glucose Monitoring Utilization in Clinical Research: Bariatric Surgery study
  • New painkillers can be developed with support of woman who don’t feel pain
  • Patients heartbroken after failure of Alzheimer's clinical trials
  • New Inclusion Policy in Clinical Research: Effective way to include all Ages
  • Shorter regimen supported by clinical trials for multidrug-resistant TB
  • A more focused trial for pancreatic cancer
  • Phase 1 Clinical Trial initiated for APVO210
  • Draft Guideline of Bioavailability Trials by FDA
  • Upcoming of Rare cancers
  • Reports of fragmentary Clinical hold on MGD009 Phase 1 study by Macrogenics (MGNX)
  • Draft Guidance Released by USFDA to conduct FIH clinical trials for Cancer Drug Developers
  • Domagrozumab (PF-06252616) clinical studies evaluating the treatment of Duchenne Muscular Dystrophy terminated by Pfizer
  • Pilot Program for encouraging the complex trial designs for Drugs and Biologics launched by USFDA
  • FDA granted Orphan Drug Designation to ASLAN003 for acute myeloid leukemia (AML) treatment
  • TrialAssure has joined hands with Otsuka Pharmaceuticals to provide its Clinical Trial Disclosure Reporting System



  • IGMPI is Conferred with QCI - D. L. Shah Quality Award

    Aligning Drug Safety and Regulatory Compliance with Argus Safety Software

    IGMPI honoured as the Jury for the FDD (Formulation Development & Drug Delivery) Leadership Awards 2017 organised by the Indian Express Group.

    All existing and old students and training participants are requested to write to our Corporate Resources division on info@igmpiindia.org along with your updated resume mentioning their Enrollment No. for registration with our Placement Cell asap, if not registered yet.

    QSSI Tech Pvt. Ltd.
    Post Graduate Diploma in Medical Coding (PGMCR 2551)
    Savyso Software
    Post Graduate Diploma in Medical Coding (PGMCR 2552)
    Ranbaxy Research Laboratories
    Executive Diploma in Pharmacovigilance (EPV 2553)
    Novartis
    Post Graduate Diploma in Clinical Research (PGCR-2559)
    International Panacea Ltd.
    Executive Diploma in Pharmacovigilance (EPV 2561)
    McCANN Health
    Post Graduate Diploma in Medical Writing (PGMW 2552)
    Alkem Healthcare
    Executive Diploma in Clinical Research (ECR-2561)
    Quintiles
    Executive Diploma in Medical Writing (EMW 2552)


    Archives

    Programmes @ IGMPI : The case study approach in an international perspective!

    IGMPI PLACEMENT BLOG


    Good Clinical Practice (GCP) Workshop@IGMPI

    Last batch placement record

    Clinical Research Programme@FCR: Case study based approach in an international perspective!


    Introduction to Clinical Research

    Introduction to Regulatory Affairs

    Introduction to Pharmacovigilance

    IGMPI's Stride: Continuing Education Programme at Merck Life Science, Bangalore,
    IGMPI Continuing Education Programme (CEP) at Merck Life Science, Bangalore on 09th & 10th July 2015 delivered by Mr. Vinod Arora (Principal Advisor, IGMPI)
    "A journey of a thousand miles begins with a single step."

    pic1
    pic1

    Recent Articles

    Use of indirect treatment comparison/network meta-analysis (NMA) study for assessment of relevance and credibility to be used in clinical research decision making by Aastha Jain

    Network meta-analysis has proved to be an important tool for prospective and retrospective observational studies for decision makers of the clinical research industry..

    Compensation models in clinical research and issues concerning India by Amrita Bhattacharya

    Compensation is offered to research subjects for participating in the clinical trials. Compensation is paid to the research subjects mainly with two objectives-for participation in the clinical trial and for trial related injuries. The compensation ..

    Liability and Indemnity in Clinical Trials and its Global Complexities by Bhawna Sharma

    Liability and indemnity both are very critical elements of clinical research process and often misunderstood. A clear understanding of liability and indemnity are very important in order to have proper risk management measures in place for clinical trials..


    Placement testimonials: Our alumni are working with Fortune 500 and global Pharmaceutical, Food and healthcare giants like: